Cargando…

Comparison of In Vitro Corneal Permeation and In Vivo Ocular Bioavailability in Rabbits of Three Marketed Latanoprost Formulations

BACKGROUND AND OBJECTIVE: All latanoprost formulations currently available for the treatment of glaucoma or ocular hypertension contain the same concentration of latanoprost (0.005%) but differ in excipients, which may affect corneal drug permeability or stability. This study aimed at comparing corn...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chauchat, Laure, Guerin, Camille, Kaluzhny, Yulia, Renard, Jean-Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2023
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10624750/ https://www.ncbi.nlm.nih.gov/pubmed/37682463 http://dx.doi.org/10.1007/s13318-023-00853-5

Ejemplares similares

Impact of Latanoprost Antiglaucoma Eyedrops and Their Excipients on Toxicity and Healing Characteristics in the Ex Vivo Eye Irritation Test System
por: Panfil, Claudia, et al.
Publicado: (2023)

Ocular ketoconazole-loaded proniosomal gels: formulation, ex vivo corneal permeation and in vivo studies
por: Abdelbary, Ghada A., et al.
Publicado: (2017)

Cost-Utility Analysis of STN1013001, a Latanoprost Cationic Emulsion, versus Other Latanoprost Formulations (Latanoprost) in Open-Angle Glaucoma or Ocular Hypertension and Ocular Surface Disease in France
por: Lazzaro, Carlo, et al.
Publicado: (2022)

Corneal Alterations Induced by Topical Application of Commercial Latanoprost, Travoprost and Bimatoprost in Rabbit
por: Chen, Wensheng, et al.
Publicado: (2014)

Comparison of the ocular tolerability of a latanoprost cationic emulsion versus conventional formulations of prostaglandins: an in vivo toxicity assay
por: Liang, Hong, et al.
Publicado: (2009)

Correction: Corneal Alterations Induced by Topical Application of Commercial Latanoprost, Travoprost and Bimatoprost in Rabbit
Publicado: (2014)

In-vivo inhibition of latanoprost induced iridal hyperpigmentation in rabbits- An investigational study
por: Sadiq, Muhammad, et al.
Publicado: (2022)

Ocular Tolerability of Preservative-Free Tafluprost and Latanoprost: in vitro and in vivo Comparative Study
por: Esaki, Yoshihiko, et al.
Publicado: (2016)

Hydrogels as Corneal Stroma Substitutes for In Vitro Evaluation of Drug Ocular Permeation
por: Burgalassi, Susi, et al.
Publicado: (2022)

Effects of the Glaucoma Drugs Latanoprost and Brimonidine on Corneal Temperature
por: Konieczka, Katarzyna, et al.
Publicado: (2019)

Differential activity and clinical utility of latanoprost in glaucoma and ocular hypertension
por: Pacella, Fernanda, et al.
Publicado: (2012)

Enhanced Ocular Anti-Aspergillus Activity of Tolnaftate Employing Novel Cosolvent-Modified Spanlastics: Formulation, Statistical Optimization, Kill Kinetics, Ex Vivo Trans-Corneal Permeation, In Vivo Histopathological and Susceptibility Study
por: Aziz, Diana, et al.
Publicado: (2022)

“Rapid and reversible alteration in corneal contour and power associated with Netarsudil/Latanoprost”
por: Chung, David, et al.
Publicado: (2022)

Implementing polymeric pseudorotaxanes for boosting corneal permeability and antiaspergillus activity of tolnaftate: formulation development, statistical optimization, ex vivo permeation and in vivo assessment
por: Aziz, Diana, et al.
Publicado: (2022)

Uveitis-induced Refractory Ocular Hypotony Managed with High-dose Latanoprost
por: Ghassemi, Fariba, et al.
Publicado: (2020)

Ocular lamellar crystalline gels for sustained release and enhanced permeation of resveratrol against corneal neovascularization
por: Li, Minshu, et al.
Publicado: (2021)

In vivo comet assay in rabbit corneal epithelial cells following ocular instillation with genotoxic compounds
por: Tahara, Haruna, et al.
Publicado: (2021)

Ex-Vivo Trans-Corneal and Trans-Scleral Diffusion Studies with Ocular Formulations of Glutathione as an Antioxidant Treatment for Ocular Diseases
por: Sebastián-Morelló, María, et al.
Publicado: (2020)

Cost–Utility Analysis of a Latanoprost Cationic Emulsion (STN1013001) versus Other Latanoprost in the Treatment of Open-Angle Glaucoma or Ocular Hypertension and Concomitant Ocular Surface Disease in Germany
por: Lazzaro, Carlo, et al.
Publicado: (2022)

Conjunctival and corneal reactions in rabbits following short- and repeated exposure to preservative-free tafluprost, commercially available latanoprost and 0.02% benzalkonium chloride
por: Liang, H, et al.
Publicado: (2008)

Study the Antifungal and Ocular Permeation of Ketoconazole from Ophthalmic Formulations Containing Trans-Ethosomes Nanoparticles
por: Ahmed, Tarek A., et al.
Publicado: (2021)

The Effect of Rebamipide on Ocular Surface Disorders Induced by Latanoprost and Timolol in Glaucoma Patients
por: Tokuda, Naoto, et al.
Publicado: (2015)

Effects of Latanoprost and Bimatoprost on the Expression of Molecules Relevant to Ocular Inflow and Outflow Pathways
por: Li, Xiaohong, et al.
Publicado: (2016)

Latanoprost PF vs. Bimatoprost PF: Which Treats the Ocular Surface Better?
por: Dimtsas, Georgios S., et al.
Publicado: (2023)

New Preservative-Free Formulation for the Enhanced Ocular Bioavailability of Prostaglandin Analogues in Glaucoma
por: Alviset, Gabriel, et al.
Publicado: (2022)

Corneal UV Protective Effects of a Topical Antioxidant Formulation: A Pilot Study on In Vivo Rabbits
por: Palazzo, Marisa, et al.
Publicado: (2020)

Effects of Netarsudil and Latanoprost Alone and in Fixed Combination on Corneal Endothelium and Corneal Thickness: Post-Hoc Analysis of MERCURY-2
por: Wisely, C. Ellis, et al.
Publicado: (2020)

Formulation and Development of Oral Fast-Dissolving Films Loaded with Nanosuspension to Augment Paroxetine Bioavailability: In Vitro Characterization, Ex Vivo Permeation, and Pharmacokinetic Evaluation in Healthy Human Volunteers
por: Elshafeey, Ahmed Hassen, et al.
Publicado: (2021)

Effect of benzalkonium chloride-free latanoprost ophthalmic solution on ocular surface in patients with glaucoma
por: Walimbe, Tejaswini, et al.
Publicado: (2016)

The RELIEF study: Tolerability and efficacy of preservative-free latanoprost in the treatment of glaucoma or ocular hypertension
por: Misiuk-Hojlo, Marta, et al.
Publicado: (2018)

Latanoprost in the treatment of glaucoma
por: Alm, Albert
Publicado: (2014)

Ocular safety of cationic emulsion of cyclosporine in an in vitro corneal wound-healing model and an acute in vivo rabbit model
por: Liang, Hong, et al.
Publicado: (2012)

First-line latanoprost therapy in ocular hypertension or open-angle glaucoma patients: a 3-month efficacy analysis stratified by initial intraocular pressure
por: Denis, Philippe, et al.
Publicado: (2010)

Efficacy and Safety of Switching Latanoprost Monotherapy to Bimatoprost Monotherapy or Combination of Brinzolamide and Latanoprost
por: Imasawa, Mitsuhiro, et al.
Publicado: (2016)

Bioavailability of Celecoxib Formulated with Mesoporous Magnesium Carbonate—An In Vivo Evaluation
por: Zardán Gómez de la Torre, Teresa, et al.
Publicado: (2022)

Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprost
por: Katz, Gregory, et al.
Publicado: (2010)

Immunologic Corneal Graft Rejection after Administration of Topical Latanoprost: a Report of Two Patients
por: Nouri-Mahdavi, Kouros, et al.
Publicado: (2011)

Extended Latanoprost Release from Commercial Contact Lenses: In Vitro Studies Using Corneal Models
por: Mohammadi, Saman, et al.
Publicado: (2014)

Strategies for Improving Ocular Drug Bioavailability and Corneal Wound Healing with Chitosan-Based Delivery Systems
por: Irimia, Teodora, et al.
Publicado: (2018)

A Novel Vitamin E TPGS-Based Formulation Enhances Chlorhexidine Bioavailability in Corneal Layers
por: Caruso, Ciro, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7rqrpg7shr2hrc41qoigeok0lv